<?xml version="1.0" encoding="UTF-8"?>
<paload id="" version="">
	<toplevel>
		<routedMedId>22255</routedMedId>
		<routedMedName>Tracleer oral</routedMedName>
		<routedGenericName>bosentan oral</routedGenericName>
		<etcIds>
			<etc_id>4549</etc_id>
		</etcIds>
		<medIds>
			<medId>206985</medId>
			<medId>245792</medId>
		</medIds>
	</toplevel>
	<diagnoses>
		<diagnosis>
			<fqn>Pulmonary Hypertensive Arterial Disease</fqn>
			<age>
				<ageRangeType>ge</ageRangeType>
				<ageRangeMin>18</ageRangeMin>
				<ageRangeMax/>
				<ageRangeUnit>y</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9>22.13784</icd9>
			<symbolic>Tracleer-PAH</symbolic>
			<rating>labeledDx</rating>
			<genotype>
				<name></name>
			</genotype>
			<polymorphism>
				<name></name>
			</polymorphism>
			<subtype_name>
				<name></name>
			</subtype_name>
			<severity>
				<name></name>
				<code></code>
				<dur></dur>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name/>
					<code/>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name></subtype_name>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur></dur>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy>
			  <criteriaSet>
			    <patientHxType>
			      <typeName>nocode</typeName>
			      <treatment>
			        <treatmentLine>
			          <interventionType>drug</interventionType>
			          <name></name>
			          <codeValues/>
			        </treatmentLine>
			      </treatment>
			    </patientHxType>
			    <preferredTherapy>
			      <treatment>
			        <dosing></dosing>
			        <rating>rtherapy</rating>
			        <treatmentLine>
			          <interventionType>drug</interventionType>
			          <name/>
			          <codeValues/>
			          <durModifier>nocode</durModifier>
			          <dur/>
			          <durUnit>nocode</durUnit>
			          <timeFrame>nocode</timeFrame>
			        </treatmentLine>
			      </treatment>
			    </preferredTherapy>
			  </criteriaSet>
			</concurrenttherapy>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>nocode</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</triedTherapyExclusion>
		  <concurrentTherapyExclusion>
		    <criteriaSet>  
		      <excludedTherapy>
		        <treatment>  
		          <treatmentLine> 
		            <option>WITH</option>
		            <interventionType>drug</interventionType>
		            <name/>
		            <codeValues/>
		            <selectedListName/>
		            <selectedListClassCode/>
		          </treatmentLine>
		        </treatment>
		      </excludedTherapy>
		    </criteriaSet>
		  </concurrentTherapyExclusion>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Tracleer bosentan tablets. Physician Prescribing Information [Internet] Actelion Pharmaceuticals US, Inc. 2012 Oct Accessed at: http://www.tracleer.com/. [accessed 2013 Dec 2]</reference>
				<reference>O'Callaghan DS, et al. Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy 2011;12(10):1585-96. DOI: 10.1517/14656566.2011.564159.</reference>
				<reference>Mathier MA, Ishizawar D. Bosentan. Expert Opinion on Pharmacotherapy 2010;11(6):1023-34. DOI: 10.1517/14656561003691854.</reference>
				<reference>Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European Heart Journal 2009;30(20):2493-537. DOI: 10.1093/eurheartj/ehp297. (Reaffirmed 2013 Nov)</reference>
				<reference>McLaughlin VV, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension. Journal of the American College of Cardiology 2009;53(17):1573-619. DOI: 10.1016/j.jacc.2009.01.004. (Reaffirmed 2013 Nov)</reference>
				<reference>Barst RJ, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. Journal of the American College of Cardiology 2009;54(1 Suppl):S78-84. DOI: 10.1016/j.jacc.2009.04.017.</reference>
				<reference>Liu C, Chen J, Gao Y, Deng B, Liu K. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No.: CD004434. DOI: 10.1002/14651858.CD004434.pub5.</reference>
				<reference>He B, et al. Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension. Circulation Journal 2010;74(7):1458-64.</reference>
				<reference>Ryerson CJ, Nayar S, Swiston JR, Sin DD. Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. Respiratory Research 2010;11:12. DOI: 10.1186/1465-9921-11-12.</reference>
				<reference>Simonneau G, et al. Updated clinical classification of pulmonary hypertension. Journal of the American College of Cardiology 2009;54(1 Suppl):S43-54. DOI: 10.1016/j.jacc.2009.04.012.</reference>
				<reference>Baumgartner H, et al. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). European Heart Journal 2010;31(23):2915-57. DOI: 10.1093/eurheartj/ehq249.</reference>
				<reference>Gupta V, Tonelli AR, Krasuski RA. Congenital heart disease and pulmonary hypertension. Heart Failure Clinics 2012;8(3):427-45. DOI: 10.1016/j.hfc.2012.04.002.</reference>
				<reference>Nakanishi N, European Society of Cardiology, European Respiratory Society. 2009 ESC/ERS pulmonary hypertension guidelines and connective tissue disease. Allergology International 2011;60(4):419-24. DOI: 10.2332/allergolint.11-RAI-0362. (Reaffirmed 2013 Nov)</reference>
				<reference>Walker KM, Pope J, participating members of the Scleroderma Clinical Trials Consortium (SCTC), Canadian Scleroderma Research Group (CSRG). Treatment of systemic sclerosis complications: what to use when first-line treatment fails--a consensus of systemic sclerosis experts. Seminars in Arthritis and Rheumatism 2012;42(1):42-55. DOI: 10.1016/j.semarthrit.2012.01.003.</reference>
				<reference>Grunig E. Treatment of pulmonary arterial hypertension in connective tissue disease. Drugs 2012;72(8):1039-56. DOI: 10.2165/11633390-000000000-00000.</reference>
				<reference>McLaughlin V, Humbert M, Coghlan G, Nash P, Steen V. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology 2009;48 Suppl 3:iii25-31. DOI: 10.1093/rheumatology/kep107.</reference>
				<reference>Janda S, Quon BS, Swiston J. HIV and pulmonary arterial hypertension: a systematic review. HIV Medicine 2010;11(10):620-34. DOI: 10.1111/j.1468-1293.2010.00829.x.</reference>
				<reference>Safdar Z, Bartolome S, Sussman N. Portopulmonary hypertension: an update. Liver Transplantation 2012;18(8):881-91. DOI: 10.1002/lt.23485.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
		<diagnosis>
			<fqn>Digital Ulcers Associated with Systemic Sclerosis-inconclusive or non-supportive evidence</fqn>
			<age>
				<ageRangeType>nocode</ageRangeType>
				<ageRangeMin/>
				<ageRangeMax/>
				<ageRangeUnit>nocode</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9/>
			<symbolic/>
			<rating>recommendedDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name/>
					<code/>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy/>
			<triedtherapy/>
			<triedTherapyExclusion/>
			<concurrentTherapyExclusion/>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Matucci-Cerinic M, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases 2011;70(1):32-8. DOI: 10.1136/ard.2010.130658.</reference>
				<reference>Dhillon S. Bosentan: a review of its use in the management of digital ulcers associated with systemic sclerosis. Drugs 2009;69(14):2005-24. DOI: 10.2165/10489160-000000000-00000.</reference>
				<reference>Opitz C, Klein-Weigel PF, Riemekasten G. Systemic sclerosis - a systematic overview: part 2 - immunosuppression, treatment of SSc-associated vasculopathy, and treatment of pulmonary arterial hypertension. VASA. Zeitschrift fur Gefasskrankheiten. Journal for Vascular Diseases 2011;40(1):20-30. DOI: 10.1024/0301-1526/a000066.</reference>
				<reference>Nguyen VA, Eisendle K, Gruber I, Hugl B, Reider D, Reider N. Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study. Rheumatology 2010;49(3):583-7. DOI: 10.1093/rheumatology/kep413.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
		<diagnosis>
			<fqn>Idiopathic Pulmonary Fibrosis-inconclusive or non-supportive evidence</fqn>
			<age>
				<ageRangeType>nocode</ageRangeType>
				<ageRangeMin/>
				<ageRangeMax/>
				<ageRangeUnit>nocode</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9>12.J84.112</icd9>
			<symbolic/>
			<rating>recommendedDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name/>
					<code/>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy/>
			<triedtherapy/>
			<triedTherapyExclusion/>
			<concurrentTherapyExclusion/>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>King TE, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 2008;177(1):75-81. DOI: 10.1164/rccm.200705-732OC.</reference>
				<reference>King TE, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 2011;184(1):92-9. DOI: 10.1164/rccm.201011-1874OC.</reference>
				<reference>Raghu G, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. American Journal of Respiratory and Critical Care Medicine 2011;183(6):788-824. DOI: 10.1164/rccm.2009-040GL.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
		<diagnosis>
			<fqn>Inoperable or Failed Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Arterial Hypertension-inconclusive or non-supportive evidence</fqn>
			<age>
				<ageRangeType>nocode</ageRangeType>
				<ageRangeMin/>
				<ageRangeMax/>
				<ageRangeUnit>nocode</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9/>
			<symbolic/>
			<rating>recommendedDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name/>
					<code/>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy/>
			<triedtherapy/>
			<triedTherapyExclusion/>
			<concurrentTherapyExclusion/>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Mathier MA, Ishizawar D. Bosentan. Expert Opinion on Pharmacotherapy 2010;11(6):1023-34. DOI: 10.1517/14656561003691854.</reference>
				<reference>Jais X, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. Journal of the American College of Cardiology 2008;52(25):2127-34. DOI: 10.1016/j.jacc.2008.08.059.</reference>
				<reference>Becattini C, Manina G, Busti C, Gennarini S, Agnelli G. Bosentan for chronic thromboembolic pulmonary hypertension: findings from a systematic review and meta-analysis. Thrombosis Research 2010;126(1):e51-6. DOI: 10.1016/j.thromres.2010.01.007.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
		<diagnosis>
			<fqn>Pulmonary Arterial Hypertension due to Heart Failure with Severe Systolic Dysfunction-inconclusive or non-supportive evidence</fqn>
			<age>
				<ageRangeType>nocode</ageRangeType>
				<ageRangeMin/>
				<ageRangeMax/>
				<ageRangeUnit>nocode</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9/>
			<symbolic/>
			<rating>recommendedDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name/>
					<code/>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy/>
			<triedtherapy/>
			<triedTherapyExclusion/>
			<concurrentTherapyExclusion/>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Kaluski E, et al. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension--a multi-center randomized study. Cardiology 2008;109(4):273-80. DOI: 10.1159/000107791.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
		<diagnosis>
			<fqn>Pulmonary Arterial Hypertension due to Sarcoidosis-inconclusive or non-supportive evidence</fqn>
			<age>
				<ageRangeType>nocode</ageRangeType>
				<ageRangeMin/>
				<ageRangeMax/>
				<ageRangeUnit>nocode</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9/>
			<symbolic/>
			<rating>recommendedDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name/>
					<code/>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy/>
			<triedtherapy/>
			<triedTherapyExclusion/>
			<concurrentTherapyExclusion/>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Barnett CF, et al. Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. Chest 2009;135(6):1455-61. DOI: 10.1378/chest.08-1881.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
		<diagnosis>
			<fqn>Pulmonary Arterial Hypertension due to Severe Chronic Obstructive Pulmonary Disease-inconclusive or non-supportive evidence</fqn>
			<age>
				<ageRangeType>nocode</ageRangeType>
				<ageRangeMin/>
				<ageRangeMax/>
				<ageRangeUnit>nocode</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9/>
			<symbolic/>
			<rating>recommendedDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name/>
					<code/>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy/>
			<triedtherapy/>
			<triedTherapyExclusion/>
			<concurrentTherapyExclusion/>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Stolz D, et al. A randomised, controlled trial of bosentan in severe COPD. European Respiratory Journal 2008;32(3):619-28. DOI: 10.1183/09031936.00011308.</reference>
				<reference>Valerio G, Bracciale P, Grazia D'Agostino A. Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. Therapeutic Advances in Respiratory Disease 2009;3(1):15-21. DOI: 10.1177/1753465808103499.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
		<diagnosis>
			<fqn>Pulmonary Arterial Hypertension due to Sickle Cell Disease-inconclusive or non-supportive evidence</fqn>
			<age>
				<ageRangeType>nocode</ageRangeType>
				<ageRangeMin/>
				<ageRangeMax/>
				<ageRangeUnit>nocode</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9/>
			<symbolic/>
			<rating>recommendedDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name/>
					<code/>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy/>
			<triedtherapy/>
			<triedTherapyExclusion/>
			<concurrentTherapyExclusion/>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Barst RJ, et al. Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. British Journal of Haematology 2010;149(3):426-35. DOI: 10.1111/j.1365-2141.2010.08097.x.</reference>
				<reference>Minniti CP, Machado RF, Coles WA, Sachdev V, Gladwin MT, Kato GJ. Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease. British Journal of Haematology 2009;147(5):737-43. DOI: 10.1111/j.1365-2141.2009.07906.x.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
		<diagnosis>
			<fqn>Pulmonary Hypertension due to Chronic Thromboembolic Disease in Patients Prior to Pulmonary Thromboendarterectomy-inconclusive or non-supportive evidence</fqn>
			<age>
				<ageRangeType>nocode</ageRangeType>
				<ageRangeMin/>
				<ageRangeMax/>
				<ageRangeUnit>nocode</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9/>
			<symbolic/>
			<rating>recommendedDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name/>
					<code/>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy/>
			<triedtherapy/>
			<triedTherapyExclusion/>
			<concurrentTherapyExclusion/>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Jensen KW, et al. Pulmonary hypertensive medical therapy in chronic thromboembolic pulmonary hypertension before pulmonary thromboendarterectomy. Circulation 2009;120(13):1248-54. DOI: 10.1161/CIRCULATIONAHA.109.865881.</reference>
				<reference>Reesink HJ, et al. Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. Journal of Thoracic and Cardiovascular Surgery 2010;139(1):85-91. DOI: 10.1016/j.jtcvs.2009.03.053.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
	</diagnoses>
	<precautions>
		<geriatric>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</geriatric>
		<pregnancy>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</pregnancy>
		<pediatric>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</pediatric>
		<lactation>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</lactation>
		<allergy>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</allergy>
		<sideEffect>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</sideEffect>
		<drugDisease>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</drugDisease>
	</precautions>
	<lists>
	</lists>
</paload>
